January 18, 2017 2:03 PM ET


Company Overview of Vaccinex, Inc.

Company Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of human therapeutic monoclonal antibodies and other targeted biological therapies. The company’s clinical programs include VX15 Immuno-Oncology, an immuno-modulating, monoclonal antibody that targets Semaphorin 4D (SEMA4D, CD100); VX15 Neurology, an anti-SEMA4D therapy for neuroinflammatory/neurodegenerative disease; VX5 Autoimmune, an anti-CXCL13 antibody for the treatment of autoimmune disorders; and NKT vaccines. The company also provides ActivMAb, an antibody discovery and optimization platform that combines the advantages of viral panning and cell sorting to enable the efficient identificat...

1895 Mount Hope Avenue

Rochester, NY 14620

United States

Founded in 1997





Key Executives for Vaccinex, Inc.

Co-Founder, Chief Executive Officer, President and Director
Chief Financial Officer
Chief Operating Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President of Research
Senior Vice President of Development
Compensation as of Fiscal Year 2016.

Vaccinex, Inc. Key Developments

Vaccinex, Inc. Presents at LifeSci Advisors' Corporate Access Event, Jan-09-2017

Vaccinex, Inc. Presents at LifeSci Advisors' Corporate Access Event, Jan-09-2017 . Venue: Sir Francis Drake Hotel, San Francisco, California, United States.

Vaccinex, Inc. Presents at NY/NJ CEO Conference, Nov-02-2016 11:35 AM

Vaccinex, Inc. Presents at NY/NJ CEO Conference, Nov-02-2016 11:35 AM. Venue: Apella at Alexandria Center, 450 E. 29 Street, New York, NY 10016, United States. Speakers: Maurice Zauderer, Co-Founder, Chief Executive Officer, President and Director.

Vaccinex, Inc. Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer

Vaccinex, Inc. announced that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, to evaluate VX15/2503, an investigational humanized anti-semaphorin 4D IgG4 monoclonal antibody, in combination with avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have not previously received immunotherapy. Vaccinex will be responsible for conducting the planned Phase Ib/II clinical trial. In preclinical studies, anti-semaphorin 4D antibodies have been shown to increase infiltration of tumoricidal immune cells while simultaneously reducing multiple types of immunosuppressive cells in tumors. Anti-semaphorin 4D antibody was found to synergize with a checkpoint inhibitor antibody to promote tumor eradication.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Vaccinex, Inc., please visit www.vaccinex.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.